The North America cell-based immunotherapy market is witnessing significant growth, supported by advanced healthcare infrastructure, strong research capabilities, and increasing adoption of cellular therapies. CAR-T therapies remain an important component of the regional landscape, while development of CAR-NK, TCR-T, and other emerging platforms is expanding the therapeutic pipeline. Continued...